US Pharma MarketingInhibrx says combo therapy shrank more tumors than Merck
The combination of Keytruda and Inhibrx’s experimental drug shrank more tumors than Keytruda alone in patients with metastatic head and neck cancer who hadn’t received treatment before. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR…
San Diego-based biotech Inhibrx is claiming that it outperformed Merck’s Keytruda in a difficult-to-treat cancer.
The combination of Keytruda and Inhibrx’s experimental drug INBRX-106 shrank more tumors than Keytruda alone in patients with metastatic head ...
Source: Endpoints News